Solutions are built by creative design coupled with proactive execution and are stimulated by a noble human purpose.

​

The drug discovery process begins with an awareness of a specific human need, it moves the next step when one or more scientists ask a well framed question, which preferably can be answered decisively when an operable method of data analysis and summation and experimental method are available.

We are enthusiastic about asking such important questions and facilitating the dialogue, which leads to subsequent steps of research to reach solutions.

Our committed interdependent ethos and mission critical focus on people, processes that inspire leadership, and technology enables us to design leading edge products that are reliable, usable and become valuable investments.

​

Verne Mendel brings chemistry to life in the field of mitochondrial degenerative diseases. Our people build broad and deep expertise expertise in the treatment of these diseases. We think about the meaning of scientific observations ranging from the details of one patient suffering from a rare disease or complication of a disease at a moment in time to findings in longitudinal studies on thousands of patients, from the behavior of one atom, electron or bond in a molecule to the beneficial or toxic biological effect of large classes of molecules in humans across time. We correlate and pool this data into meaningful and executable information and conclusions. We know that the journey can only be as successful as is our preparation appropriate, comprehensive and timely. Researchers realize that minute details and obscure possibilities may provide the keys to major insights, new directions and scientific advances.

​

Each day opens further doors and avenues of new knowledge. Unknowns and risks can be replaced by information supported opinions. In the biomedical researchers life the same goal is always present - To understand how the body functions in health and disease and how that function can he helped by a compatible chemistry. In today’s world the standard of that treatment must surpass previously available remedies and address the progress of disease in order to satisfy the wishes of consumers and payers. Because neurodegenerative and metabolic diseases are major human burdens on patients and families and cause very large economic costs on society the advantages of better treatments are eagerly welcomed.

​

Our people and investors are motivated to share the benefits of this work with every patient whose health and wellbeing can be enhanced by it.

​

Research & Development

​

Mitochondria are organelles in cells, which produce an energy-containing compound, adenosine triphosphate (ATP). These powerhouses convert the energy in foodstuffs to the compound ATP which stores energy, which is used to effect many cellular activities. The electron transport chain, a series of proteins arranged like a production line, produces the ATP. Two very small strands of mitochondrial DNA code for some of these proteins. This DNA may be mutated or deleted resulting in hereditary diseases such as Batten’s disease, which is a form of dementia, or Leigh’s disease. Mitochondrial DNA is also damaged by organic chemicals catalyzed by heavy metals resulting in diseases such as Parkinson’s and Alzheimer’s diseases and Type II diabetes.

​

Mitochondrial DNA has protection systems, which are less evolved than those of nuclear DNA, which protect it against environmental toxins such as the Parkinson inducing agent, MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), the diabetogenic toxin streptozotocin and endogenous compounds such as dopamine. We discovered compounds which exert multiple controls on the access of organic molecules and heavy metals to DNA bases, affecting transport mechanisms, transcription of DNA and other DNA enzyme activities. individual DNA actions may be influenced by other chemicals; however, these compound families are unique in their comprehensive range of DNA base protective actions.

​

The Company initially discovered a means of preventing MPTP Parkinsonism, MPTP being a toxin, which causes mitochondrial DNA damage and inhibits mitochondrial respiration. This is the first non-toxic means of preventing MPTP and MPP+ (cation 1-methyl-4-Mitochondrial DNA has protection systems, which are less evolved than those of nuclear DNA, which protect it against environmental toxins such as the Parkinson inducing agent, MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), the diabetogenic toxin streptozotocin and endogenous compounds such as dopamine. We disocvered compounds which exert multiple controls on the access of organic molecules and heavy metals to DNA bases, affecting transport mechanisms, transcription of DNA and other DNA enzyme activities. Individual DNA actions may be influenced by other chemicals; however, these compound families are unique in their comprehensive range of DNA base protective actions.pMitochondrial DNA has protection systems, which are less evolved than those of nuclear DNA, which protect it against environmental toxins such as the Parkinson inducing agent, MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), the diabetogenic toxin streptozotocin and endogenous compounds such as dopamine. We disocvered compounds which exert multiple controls on the access of organic molecules and heavy metals to DNA bases, affecting transport mechanisms, transcription of DNA and other DNA enzyme activities. Individual DNA actions may be influenced by other chemicals; however, these compound families are unique in their comprehensive range of DNA base protective actions.

​

henylpyridinium) induced biochemical damage. Introduction of defective mitochondrial genes into cybid cell lines causes induction of apoptosis (programmed cell death) and increased production of amyloid by the cells.

​

As with neurodegeneration, there are several other environmentally induced diseases including diabetes and its complications, which are major medical problems and hence present scientific and market opportunities for Verne Mendel Medical’s technology.

s, transcription of DNA and other DNA enzyme activities. Individual DNA actions may be influenced by other chemicals; however, polyamines are unique in their comprehensive range of DNA base protective actions. Verne Mendel Medical’s scientific task is to work with nature’s own mechanism of DNA base protection and optimize it to address the particular toxic events occurring in individual diseases.

​

The Company’s initially discovered a means of preventing MPTP Parkinsonism, MPTP being a toxin, which causes mitochondrial DNA damage and inhibits mitochondrial respiration. This is the first non-toxic means of preventing MPTP and MPP+ (cation 1-methyl-4-phenylpyridinium) induced biochemical damage. Introduction of defective mitochondrial genes into cybid cell lines causes induction of apoptosis and increased production of amyloid by the cells.

​

As with neurodegeneration, there are several other environmentally induced diseases including diabetes and its complications, which are major medical problems and hence present scientific and market opportunities for Verne Mendel Medical’s technology.